Cargando…
Epidermolytic hyperkeratosis: clinical update
Epidermolytic hyperkeratosis (EHK), earlier termed as bullous congenital ichthyosiform erythroderma is a skin disorder characterized as an autosomal dominant and rare disorder which has been observed to affect 1 in over 200,000 infants as a consequence of a significant mutation in the genes responsi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512611/ https://www.ncbi.nlm.nih.gov/pubmed/31190940 http://dx.doi.org/10.2147/CCID.S166849 |
_version_ | 1783417689911328768 |
---|---|
author | Peter Rout, Denice Nair, Anushka Gupta, Anand Kumar, Piyush |
author_facet | Peter Rout, Denice Nair, Anushka Gupta, Anand Kumar, Piyush |
author_sort | Peter Rout, Denice |
collection | PubMed |
description | Epidermolytic hyperkeratosis (EHK), earlier termed as bullous congenital ichthyosiform erythroderma is a skin disorder characterized as an autosomal dominant and rare disorder which has been observed to affect 1 in over 200,000 infants as a consequence of a significant mutation in the genes responsible for the keratin proteins, mostly keratin 1 and 10. The features present at birth include erythema and blistering. In adults, the hallmarks include hyperkeratosis, erosions, and blisters. The major symptoms including xerosis, pruritus, and painful fissuring lead not only to cosmetic problems but also stress, inferiority complex and other psychological conditions. While clinical inspection followed by confirmatory tests including histopathology and electron microscopic assessment is used for diagnosis, treatment modalities can be further improved for better diagnosis. This article reviews subtypes of ichthyosis, with a focus on EHK, genetics behind the disease, recently reported mutations, the existing diagnostics and treatments for the same and potential of new modalities in diagnosis/treatment. |
format | Online Article Text |
id | pubmed-6512611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65126112019-06-12 Epidermolytic hyperkeratosis: clinical update Peter Rout, Denice Nair, Anushka Gupta, Anand Kumar, Piyush Clin Cosmet Investig Dermatol Review Epidermolytic hyperkeratosis (EHK), earlier termed as bullous congenital ichthyosiform erythroderma is a skin disorder characterized as an autosomal dominant and rare disorder which has been observed to affect 1 in over 200,000 infants as a consequence of a significant mutation in the genes responsible for the keratin proteins, mostly keratin 1 and 10. The features present at birth include erythema and blistering. In adults, the hallmarks include hyperkeratosis, erosions, and blisters. The major symptoms including xerosis, pruritus, and painful fissuring lead not only to cosmetic problems but also stress, inferiority complex and other psychological conditions. While clinical inspection followed by confirmatory tests including histopathology and electron microscopic assessment is used for diagnosis, treatment modalities can be further improved for better diagnosis. This article reviews subtypes of ichthyosis, with a focus on EHK, genetics behind the disease, recently reported mutations, the existing diagnostics and treatments for the same and potential of new modalities in diagnosis/treatment. Dove 2019-05-08 /pmc/articles/PMC6512611/ /pubmed/31190940 http://dx.doi.org/10.2147/CCID.S166849 Text en © 2019 Peter Rout et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Peter Rout, Denice Nair, Anushka Gupta, Anand Kumar, Piyush Epidermolytic hyperkeratosis: clinical update |
title | Epidermolytic hyperkeratosis: clinical update |
title_full | Epidermolytic hyperkeratosis: clinical update |
title_fullStr | Epidermolytic hyperkeratosis: clinical update |
title_full_unstemmed | Epidermolytic hyperkeratosis: clinical update |
title_short | Epidermolytic hyperkeratosis: clinical update |
title_sort | epidermolytic hyperkeratosis: clinical update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512611/ https://www.ncbi.nlm.nih.gov/pubmed/31190940 http://dx.doi.org/10.2147/CCID.S166849 |
work_keys_str_mv | AT peterroutdenice epidermolytichyperkeratosisclinicalupdate AT nairanushka epidermolytichyperkeratosisclinicalupdate AT guptaanand epidermolytichyperkeratosisclinicalupdate AT kumarpiyush epidermolytichyperkeratosisclinicalupdate |